ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
1-Year Return
169.78%
This Quarter Return
+46.68%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$363M
AUM Growth
+$22.8M
(+6.7%)
Cap. Flow
-$33.2M
Cap. Flow
% of AUM
-9.14%
Top 10 Holdings %
Top 10 Hldgs %
48.6%
Holding
60
New
16
Increased
14
Reduced
15
Closed
8
Top Buys
| 1 |
VistaGen Therapeutics
VTGN
|
$14.6M |
| 2 |
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
|
$9.39M |
| 3 |
Replimune Group
REPL
|
$7.92M |
| 4 |
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
|
$5.79M |
| 5 |
Stoke Therapeutics
STOK
|
$5.73M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$43.5M |
| 2 |
Kura Oncology
KURA
|
$11M |
| 3 |
Aldeyra Therapeutics
ALDX
|
$9.98M |
| 4 |
Cytokinetics
CYTK
|
$7.74M |
| 5 |
LSACU
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
|
$7.62M |
Sector Composition
| 1 | Healthcare | 90.62% |
| 2 | Financials | 4.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Stoke Therapeutics
STOK
$1.21B
| $5.73M | 1.56% |
+92,500
| New | +$5.73M |
|
27
Verastem
VSTM
$638M
| $5.11M | 1.39% |
200,000
| – | – |
|
28
Orchestra BioMed
OBIO
$147M
| $5.03M | 1.37% |
392,500
| – | – |
|
|
AVDL
29
Avadel Pharmaceuticals
AVDL
$1.51B
| $4.71M | 1.28% |
705,218
| – | – |
|
30
Curis
CRIS
$22.1M
| $4.34M | 1.18% |
+26,500
| New | +$4.34M |
|
31
Praxis Precision Medicines
PRAX
$901M
| $4.16M | 1.13% |
+5,043
| New | +$4.16M |
|
32
RAPT Therapeutics
RAPT
$219M
| $4.14M | 1.13% |
26,200
-3,800
| -13% | -$600K |
|
33
Relmada Therapeutics
RLMD
$50.5M
| $3.85M | 1.05% |
120,000
-157,000
| -57% | -$5.03M |
|
34
C4 Therapeutics
CCCC
$189M
| $3.64M | 0.99% |
+110,000
| New | +$3.64M |
|
35
Madrigal Pharmaceuticals
MDGL
$9.98B
| $3.61M | 0.98% |
+32,500
| New | +$3.61M |
|
36
Clearside Biomedical
CLSD
$27.3M
| $3.43M | 0.93% |
1,250,000
+635,000
| +103% | +$1.74M |
|
|
CBAY
37
DELISTED
Cymabay Therapeutics
CBAY
| $1.89M | 0.52% |
330,000
-435,000
| -57% | -$2.5M |
|
|
ONCR
38
DELISTED
Oncorus, Inc.
ONCR
| $1.73M | 0.47% |
+53,500
| New | +$1.73M |
|
|
39
Aldeyra Therapeutics
ALDX
$338M
| $1.32M | 0.36% |
192,500
-1,454,200
| -88% | -$9.98M |
|
40
Xenon Pharmaceuticals
XENE
$2.95B
| $1.23M | 0.33% |
80,000
-220,000
| -73% | -$3.38M |
|
41
Cyclacel Pharmaceuticals
CYCC
$15.8M
| $1.17M | 0.32% |
+42
| New | +$1.17M |
|
42
Rocket Pharmaceuticals
RCKT
$351M
| $1.1M | 0.3% |
+20,000
| New | +$1.1M |
|
43
PMV Pharmaceuticals
PMVP
$73.1M
| $923K | 0.25% |
+15,000
| New | +$923K |
|
44
Wave Life Sciences
WVE
$1.23B
| $846K | 0.23% |
107,500
| – | – |
|
45
4D Molecular Therapeutics
FDMT
$333M
| $829K | 0.23% |
+20,000
| New | +$829K |
|
46
Annexon
ANNX
$243M
| $626K | 0.17% |
25,000
-85,000
| -77% | -$2.13M |
|
|
KRTX
47
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $508K | 0.14% |
5,000
-8,500
| -63% | -$864K |
|
48
Axsome Therapeutics
AXSM
$6.33B
| $489K | 0.13% |
6,000
-16,500
| -73% | -$1.34M |
|
|
PANA.WS
49
DELISTED
Panacea Acquisition Corp. Redeemable warrants, each whole warrant exercisable for one share of Class
PANA.WS
| $299K | 0.08% |
+93,332
| New | +$299K |
|
50
Novavax
NVAX
$1.25B
| $279K | 0.08% |
+2,500
| New | +$279K |
|